^
    Back
    Association details:
    Biomarker:RB1 deletion
    Cancer:Ovarian Cancer
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) +
    SRA515 (BET inhibitor, BRD4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Lett
    Title:

    AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway

    Published date:
    12/20/2021
    Excerpt:
    Moreover, this study revealed that AZD5153 and palbociclib had a synergistic lethal effect on inducing the cell cycle arrest and increasing apoptosis, even in RB-deficient cell lines. Based on these results, it is anticipated that this class of drugs, including AZD5153, which inhibit the cell cycle-related protein and MAPK/PI3K-AKT pathway, will exhibit synergistic effects with palbociclib in OC.
    DOI:
    10.1016/j.canlet.2021.12.021